11 news items
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK
18 Jun 24
States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK
17 Jun 24
in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK
3 Jun 24
health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory
px2vjq0ld2qxcoqfrkoyk
PFE
TAK
1 Jun 24
premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand
f5t4hc4sfgglxpbw euwl8mxbrc0ngh07v4v0dhyb2k5kndlsh0nzexshlt
TAK
31 May 24
States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent
rlw8v55pscd n2oexa01hfftonyvscmiq1b6ivppna42j3kabryli81z
TAK
16 May 24
for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit
ct1 wq5i9t9g4pe1t7wc2g8w8z22nkh1jr9
TAK
26 Apr 24
in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms
swdc k9ts
TAK
18 Apr 24
, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory
7cu3s12nsmvjohikujp8eov0ntp 4lw8bh2176azyev2vo
TAK
27 Mar 24
are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information
- Prev
- 1
- Next